IMPACT Therapeutics

IMPACT Therapeutics (Ticker: 7630 HK) develops precision cancer treatments designed to exploit vulnerabilities in cancer cells. Founded in 2009, IMPACT Therapeutics’ core product is senaparib, which was commercialized in China in January 2025 as a first-line maintenance treatment for ovarian cancer. The offering consists entirely of newly issued shares and includes a 15% greenshoe option. Proceeds are intended for research and development, product capacity, brand promotion, business development, working capital and strategic acquisitions.

The scheduled listing date on Hong Kong Stock Exchange was May 13, 2026. The proposed offering comprises 41,980,000 shares at an indicative price range of HKD 19.75–21.75 per share. At the indicative range midpoint, the base offering would represent HKD 871.09 million, approximately $111.00 million in gross proceeds, excluding any unexercised over-allotment. The indicated IPO market capitalization is $696.00–767.00 million.

CICC Hong Kong Securities and Goldman Sachs (Asia) are IPO sponsors.